Literature DB >> 10638703

Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells.

T Yamaoka1, S Kojima, S Ichi, Y Kashiwazaki, T Koide, Y Sokawa.   

Abstract

Nine interferon-alpha subtypes, IFN-alpha1, IFN-alpha2, IFN-alpha5, IFN-alpha7, IFN-alpha8, IFN-alpha10, IFN-alpha14, IFN-alpha17, and IFN-alpha21, were separated from purified human lymphoblastoid IFN. We tested their inhibitory effects on cell growth and replication of Semliki Forest virus (SFV) and vesicular stomatitis virus (VSV) and their induction of 2',5'-oligoadenylate synthetase (2', 5'-OAS) in ACHN renal cell carcinoma cells. In terms of all three activities, the nine subtypes had similar relative activities, with IFN-alpha10 the most active and IFN-alpha1 the least. Their relative effects on cell growth were similar in two other human cell lines, SK-LU-1 lung cancer cells and KU-2 renal cell carcinoma cells, whereas cells of the Daudi Burkitt lymphoma line behaved quite differently, being highly sensitive to all the nine subtypes. The relative effects with ACHN cells correlated well with their relative binding affinities. However, each of the subtypes bound to both ACHN and Daudi cells to almost the same extent. This suggests that their profound inhibitory effects on the growth of Daudi cells are amplified at some stage in the signal transduction pathway or in the expression of genes that results from binding to the IFN-alpha receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10638703     DOI: 10.1089/107999099312803

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  9 in total

1.  Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation.

Authors:  Catherine François; Isabelle Bernard; Sandrine Castelain; Bryan Charleston; Martin D Fray; Jean-Claude Capiod; Gilles Duverlie
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Characterization of the murine alpha interferon gene family.

Authors:  Vincent van Pesch; Hanane Lanaya; Jean-Christophe Renauld; Thomas Michiels
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 3.  IFN-α subtypes: distinct biological activities in anti-viral therapy.

Authors:  K Gibbert; J F Schlaak; D Yang; U Dittmer
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

4.  Expression of bovine interferon-tau variants according to sex and age of conceptuses.

Authors:  Angela M Walker; Koji Kimura; R Michael Roberts
Journal:  Theriogenology       Date:  2009-03-25       Impact factor: 2.740

5.  Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7.

Authors:  Pierre Génin; Rongtuan Lin; John Hiscott; Ahmet Civas
Journal:  Mol Cell Biol       Date:  2009-04-06       Impact factor: 4.272

6.  Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes.

Authors:  Sotaro Miwa; Yoshifumi Kadono; Toshiaki Sugata; Atsushi Mizokami; Mikio Namiki
Journal:  Int J Clin Oncol       Date:  2010-02       Impact factor: 3.402

Review 7.  Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure.

Authors:  Jeffy George; Joseph J Mattapallil
Journal:  Front Immunol       Date:  2018-02-22       Impact factor: 7.561

8.  IL-6 and IL-10 Are Associated With Gram-Negative and Gram-Positive Bacteria Infection in Lymphoma.

Authors:  Qiuhua Zhu; Huan Li; Shanshan Zheng; Bin Wang; Mingjie Li; Wenbin Zeng; Lanlan Zhou; Zebing Guan; Hong Wang; Yanan Liu; Yanmin Gao; Shiqiu Qiu; Chaolun Chen; Shimei Yang; Yuemei Yuan; Hanling Zhang; Guanqiao Ruan; Xueyi Pan
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 7.561

9.  Gene cloning, sequencing, expression and biological activity of giant panda (Ailuropoda melanoleuca) interferon-alpha.

Authors:  Xue-Mei Tan; Yang Tang; Yun-Fei Yang; Hong-Mei Song; Yi-Zheng Zhang
Journal:  Mol Immunol       Date:  2007-03-07       Impact factor: 4.407

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.